Thus, classifying a new prognostic CML subgroup using FLT3 expression as a biomarker will facilitate the prediction of sudden onset of BP, provide guidelines for the rational management of advanced phase CML patients, and the selection of patients for targeted clinical trials. The gene discussed is FLT3; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.